Pilot evaluation of bupropion for the treatment of hot flashes

Journal of Palliative Medicine

Volumn 9, Issue 3, 2006, Pages 631-637

  Pérez, Domingo G ^a   Loprinzi, Charles L ^a,b   Sloan, Jeff ^a   Novotny, Paul ^a   Barton, Debra ^a   Carpenter, Lisa ^a   Smith, Deanne ^a   Christensen, Brad ^a   Rummans, Teresa ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANDROGEN; AROMATASE INHIBITOR; NICOTINE; NORADRENALIN; PLACEBO; RALOXIFENE; TAMOXIFEN;

ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FIBROMYALGIA; HEADACHE; HOT FLUSH; HUMAN; MALE; NAUSEA AND VOMITING; NERVOUSNESS; QUESTIONNAIRE;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; COMORBIDITY; FEMALE; HOT FLASHES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 33745314443     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.9.631     Document Type: Article

References (44)

1. McKinlay SM, Jeffreys M: The menopausal syndrome. Br J Prev Soc Med 1974;28:108-115.
2. Tataryn IV, Lomax P, Meldrum DR, Bajorek JG, Chesarek W, Judd HL: Objective techniques for the assessment of postmenopausal hot flashes. Obstet Gynecol 1981;57:340-344.
3. Greendale GA, Lee NP, Arriola ER: The menopause. Lancet 1999;353:571-580.
4. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA: Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998;16:327-333.
5. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G: Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 2000;19:436-445.
6. Berg G, Gottwall T, Hammar M, Lindgren R: Climacteric symptoms among women aged 60-62 in Linkoping, Sweden in 1986. Maturitas 1988;10:193-199.
7. Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, Kenady D, Sloan D, Munn R: Hot flashes in postmenopausal women treated for breast carcinoma. Cancer 1998;82:1682-1691.
8. Love RR, Cameron L, Connell BL, Leventhal H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-1847.
9. Fallowfield L: Assessing the quality of life (QOL) of postmenopausal (PM) women randomized into the ATAC (Arimidex, tamoxifen, alone or in combination) adjuvant breast cancer (BC) trial [Abstract 159]. Proc Am Soc Clin Oncol 2002;21:40a.
10. Buchholz NP, Mattarelli G, Bucholz MM: Post-orchiectomy hot flushes. Eur Urol 1994;26:120-122.
11. Schow DA, Renfer LG, Rozanski TA, Thompson IM: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91:855-887.
12. Lanfrey P, Mottet N, Dagues F, Bennaoum K, Costa P, Louis JF, Navratil H: Hot flashes and hormonal treatment of prostate cancer. Prog Urol 1996;6:17-22.
13. Notelovitz M, Lenihan JP, McDermott M, Keber IJ, Nanavati N, Arce J: Initial 17-beta-estradioldose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731.
14. Garg PP, Kerlikowske K, Subak L, Grady D: Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis. Obstet Gynecol 1998;92:472-479.
15. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey EXI, Wood WC; Estrogen replacement therapy in breast cancer survivors: A time for change. JAMA 1994;272:540-545.
16. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Theriault RL: Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482.
17. Beckmann MW, Jap D, Djahansouzi S, Nestle-Kramling C, Kuschel B, Dali P, Brumm C, Bender HG: Hormone replacement therapy after treatment of breast cancer: Effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001;60:199.
18. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J: Hormone replacement therapy after breast cancer: A systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357.
19. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS: Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754.
20. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL: Estrogen replacement therapy for menopausal women with a history of breast carcinoma. Cancer 2002;95:1817.
21. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
22. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-341.
23. Chen CL, Weiss NS, Newcomb P, Barlow W, White E: Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-741.
24. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, Bate WW, Rospond RM, Oesterling JE: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-52.
25. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ: Veafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 2000;356:2059-2063.
26. Stearns V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA 2003;289:2827-2834.
27. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
28. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K: Gabapentin's effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2003;101:337-345.
29. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S: A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-166.
30. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H: Methodologie lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
31. Casper RF, Yen SS: Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22:293-312.
32. Freedman RR, Krell W: Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66-70.
33. Freedman RR, Norton D, Woodward S, Cornelissen G: Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358.
34. Bethea CL, Lu NZ, Gundlah C, Streicher JM: Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41-100.
35. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, Staley JK, Garg PK, Seibyl JP, Innis RB: Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522-1524.
36. Van Amelsvoort T, Compton J, Murphy D: In vivo assessment of the effects of estrogen on human brain. Trends Endocrinol Metab 2001;12:273-276.
37. Sumner BE, Grant KE, Rosie R, Hegele-Hartung C, Fritzemeier KH, Fink G: Effects of tamoxifen on serotonin transporter and 5-hydroxitryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Mol Brain Res 1999;73:119-128.
38. Sipe K, Leventhal L, Burroughs K, Cosmi S, Johnston GH, Deecher DC: Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res 2004;1028:191-202.
39. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL: Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218.
40. Goldberg RM, Loprinzi CL, O'Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose AM, Rowland KM, Burnham NL: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158.
41. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, Pierce HI, Dragalin V, Morrow GR: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-793.
42. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novomy PJ, Rummans TA, Dumesic DA, Perez EA: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-2381.
43. Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT, Christensen BJ: Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004;79:1247-1251.
44. Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith de AR, Pruthi S, Novotny PJ, Perez EA, Christensen BJ: Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002;77:1159-1163.